Is there a role for selective axillary dissection in breast cancer?

World Journal of Surgery

Volumn 25, Issue 6, 2001, Pages 809-818

  Gemignani, Mary L ^a   Borgen, Patrick I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LYMPH NODE DISSECTION; LYMPHOSCINTIGRAPHY; SENTINEL LYMPH NODE BIOPSY;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 0034995320     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-001-0010-y     Document Type: Article

References (107)

1. Axillary dissection: An obsolete operation?
2. Axillary dissection in breast cancer: When, why, how much, and for how long? Another operation soon to be extinct?
3. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma
4. New therapeutic possibilities in primary invasive breast cancer
5. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma
6. Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4). X. Discriminants for tenth year treatment failure
7. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes
8. Pathological prognostic factors in stage I(T1N1M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years
9. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
10. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis
11. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma
12. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2NOMO patients with long-term follow-up
13. Tubular carcinoma of the breast
14. Early Breast Cancer Trialist' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
15. Meeting highlights: Adjuvant therapy for primary breast cancer
16. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability
17. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma
18. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast
19. Factors affecting the incidence of lymph node metastases in small cancers of the breast
20. Predictors of axillary lymph node metastases in patients with T1 breast cancer: A multivariate analysis
21. Lymph node metastasis in breast cancer: Common prognostic markers lack predictive value
22. Axillary lymph node metastases associated with small invasive breast carcinomas
23. Treatment of nonpalpable breast cancer in the elderly
24. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women
25. Management of breast cancer in the elderly by complete local excision and tamoxifen alone
26. T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection
27. Patterns of breast carcinoma treatment in older women: Patient preference and clinical and physical influences
28. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection
29. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes
30. Treatment and survival of female patients with nonpalpable breast carcinoma
31. Nonpalpable invasive breast cancer
32. Aggressive axillary evaluation and adjuvant therapy for nonpalpable carcinoma of the breast
33. Impact of axillary lymph node dissection on the therapy of breast cancer patients
34. Treatment of the axilla in patients with screen-detected breast cancer
35. Management
36. Axillary lymph node dissection for T1a breast carcinoma: Is it indicated?
37. The value of axillary dissection in T1a breast cancer
38. Axillary lymph node dissection: Is it required in T1a breast cancer?
39. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma
40. Infiltrating breast carcinoma smaller than 0.5 centimeters: Is lymph node dissection necessary?
41. Predictors of axillary lymph node metastasis in T1 breast carcinoma
42. Axillary lymph node dissection in breast cancer: An evolving question?
43. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: Analysis in more than 900 patients
44. The need to re-examine axillary lymph node dissection in invasive breast cancer
45. Patient preferences for axillary dissection in the management of early-stage breast cancer
46. Patients with early breast cancer benefit from effective axillary treatment
47. Axillary node dissection for early breast cancer: Some is good, but all is better
48. Comparison of radical mastectomy with alternative treatments for primary breast cancer
49. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
50. Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer
51. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: Influence of axillary dissection for treatment of T1a and T1b lesions
52. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer
53. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer
54. Discontinuous or "skip" metastases in breast carcinoma: Analysis of 1228 axillary dissections
55. Technical details of intraoperative lymphatic mapping for early stage melanoma
56. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
57. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe
58. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
59. Sentinel lymphadenectomy in breast cancer
60. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
61. Lymphatic mapping in the treatment of breast cancer
62. The sentinel node in breast cancer: A multicenter validation study
63. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer
64. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer
65. Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection
66. Gamma-probe-guided resection of the sentinel lymph node in breast cancer
67. Can sentinel node biopsy avoid axillary dissection in clinically node-negative breast cancer patients?
68. Sentinel lymph node localization in early breast cancer
69. Development of sentinel node targeting technique in breast cancer patients
70. Ultrasonographically guided injection improves localization of the radiolabeled sentinel lymph node in breast cancer
71. Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled Dextran
72. Sentinel lymph node biopsy for staging breast cancer
73. Sentinel node biopsy in the staging of breast cancer
74. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy
75. Unfiltered sulfur colloid and sentinel node biopsy for breast cancer: Technical and kinetic considerations
76. Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series
77. Sentinel lymphadenectomy for breast cancer in a community managed care setting
78. Axillary staging utilizing selective sentinel lymphadenectomy for patients with invasive breast carcinoma
79. Sentinel node localization in patients with breast cancer
80. Identification and biopsy of the sentinel lymph node in breast cancer
81. Sentinel lymph node involvement - A predictor for axillary node status with breast cancer - Has the time come?
82. Experience with lymphatic mapping in breast cancer using isosulfan blue dye
83. Initial experience with sentinel node biopsy in breast cancer at the National Cancer Center Hospital East
84. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye
85. Initial experience in a community hospital with sentinel lymph node mapping and biopsy for evaluation of axillary lymph node status in palpable invasive breast cancer
86. Leaning sentinel node biopsy: Results of a prospective randomized trial of two techniques
87. Intradermal blue dye to identify sentinel lymph node in breast cancer
88. Sentinel node biopsy in breast cancer
89. Sentinel lymph node mapping opens a new perspective in the surgical management of early-stage breast cancer: A combined approach with vital blue dye lymphatic mapping and radioguided surgery
90. Sentinel lymph node biopsy, an alternative to elective axillary dissection for breast cancer
91. Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center
92. Gamma probe-guided sentinel node biopsy - Optimal timing for injection
93. The role of sentinel lymph node biopsy in breast cancer
94. Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer
95. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma
96. The feasibility and accuracy of the sentinel lymph node biopsy for breast carcinoma
97. Sentinel node biopsy in 70 unselected patients with breast cancer: Increased feasibility by using 10 mCi radiocolloid in combination with a blue dye tracer
98. Sentinel lymph node biopsy in breast cancer: Review of published experience
99. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma
100. Lessons learned from 500 cases of lymphatic mapping for breast cancer
101. Lymphovascular invasion enhances the prediction of nonsentinel node metastases in breast cancer patients with positive sentinel nodes
102. Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer
103. Is routine intraoperative frozen-section examination of sentinel lymph nodes in breast cancer worthwhile?
104. Impact of sentinel lymph node mapping on relative charges in patients with early-stage breast cancer
105. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy
106. Long-term follow-up of breast cancer patients: The 30-year report
107. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18